BEZ235通过靶向内皮细胞Akt/4EBP1/细胞周期蛋白D1通路抑制视网膜新生血管
本研究在氧诱导视网膜病变(OIR)小鼠模型及人脐静脉内皮细胞(HUVEC)、人视网膜微血管内皮细胞(HRMEC)中探究双重PI3K/mTOR抑制剂BEZ235抑制病理性新生血管的疗效及细胞周期蛋白D1的作用。BEZ235通过抑制PI3K/Akt/mTOR通路、降低Akt与4EBP1磷酸化而下调细胞周期蛋白D1,显著抑制内皮细胞周期进展、增殖、迁移和成管,并在OIR模型中减少新生血管、改善血管组织;所用剂量下未见明显视网膜或全身毒性。
要点
- BEZ235在体外显著抑制HUVEC和HRMEC的细胞活力、增殖、迁移和成管。
- BEZ235通过下调细胞周期蛋白D1诱导G0/G1期阻滞。
- 在OIR小鼠模型中BEZ235显著减少视网膜新生血管并改善血管组织。
核心结论
- BEZ235通过抑制4EBP1磷酸化下调细胞周期蛋白D1,有效抑制视网膜新生血管,提示其可能成为视网膜新生血管疾病的治疗药物。
研究设计与样本
- 研究采用氧诱导视网膜病变(OIR)小鼠模型,并体外评估BEZ235对人脐静脉内皮细胞(HUVEC)和人视网膜微血管内皮细胞(HRMEC)的影响。
- 采用单细胞RNA测序分析常氧与OIR条件下视网膜内皮细胞的基因表达和细胞周期改变。
- 在OIR模型中通过视网膜铺片免疫荧光染色、苏木精-伊红(H&E)染色、RT-qPCR和western blot评估视网膜新生血管。
- 通过视网膜电图(ERG)及心、肝、脾、肺、肾组织学检查评估BEZ235的体内毒性。
主要发现
- 体外实验中,BEZ235在mRNA和蛋白水平下调细胞周期蛋白D1,诱导G0/G1期阻滞,并显著降低细胞活力、增殖、迁移和成管能力。
- 在OIR模型中,BEZ235显著减少新生血管并改善血管组织。
- BEZ235通过抑制PI3K/Akt/mTOR通路、降低Akt和4E结合蛋白1(4EBP1)磷酸化水平而下调细胞周期蛋白D1表达。
- ERG和组织学检查提示,在抑制视网膜新生血管所用剂量下,BEZ235未引起明显的视网膜或全身毒性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the therapeutic efficacy of BEZ235, a dual PI3K/mTOR inhibitor, in suppressing pathological neovascularization in an oxygen-induced retinopathy (OIR) mouse model and explore the role of cyclin D1 in endothelial cell cycle regulation. METHODS: Single-cell RNA sequencing was performed to analyze gene expression and cell-cycle alterations in retinal endothelial cells under normoxic and OIR conditions. The effects of BEZ235 on human umbilical vein endothelial cells (HUVECs) and human retinal microvascular endothelial cells (HRMECs) were evaluated by assessing cell viability, cell-cycle progression, proliferation, migration, and tube formation. In the OIR mouse model, retinal neovascularization was evaluated by retinal flatmount immunofluorescence staining, hematoxylin and eosin (H&E) staining, quantitative reverse-transcription polymerase chain reaction (RT-qPCR), and western blot analyses. The in vivo toxicity of BEZ235 was evaluated by electroretinography (ERG) and histological examination of the heart, liver, spleen, lungs, and kidneys. RESULTS: In vitro, BEZ235 significantly inhibited cell cycle progression by downregulating cyclin D1 at both mRNA and protein levels, inducing G0/G1 phase arrest. This led to significant reductions in cell viability, proliferation, migration, and tube formation. In the OIR model, BEZ235 substantially decreased neovascularization and improved vascular organization. BEZ235 mediates its effects by inhibiting the PI3K/Akt/mTOR pathway, reducing Akt and 4E-binding protein 1 (4EBP1) phosphorylation levels, thus downregulating cyclin D1 expression. ERG and histological examination suggested that BEZ235 did not induce evident retinal or systemic toxicity at the dosage used to inhibit retinal neovascularization. CONCLUSIONS: BEZ235 effectively inhibits retinal neovascularization by downregulating cyclin D1 via 4EBP1 phosphorylation inhibition, highlighting its potential as a promising therapeutic agent for retinal neovascularization diseases.
引用
- Liu Q, Xia LX, Yi WZ, et al. Inhibition of Retinal Neovascularization by BEZ235: Targeting the Akt/4EBP1/Cyclin D1 Pathway in Endothelial Cells. Invest Ophthalmol Vis Sci. 2025. PMID: 39888634. doi:10.1167/iovs.66.1.66
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。